Wockhardt’s new drug, India’s second to get US nod, now eyes commercial success

Wockhardt’s antibiotic Zaynich received US regulatory approval on Saturday, marking India’s second homegrown new drug (NCE) without foreign collaboration. Developed at an $800 million investment, Zaynich treats complicated urinary tract infections (UTI) and follows Orchid Pharma’s enmetazobactam, India’s first NCE, approved in 2024 with a European partner. The company secured US approval independently, having already gained Indian clearance last week. Wockhardt plans domestic launches in five months and expects European and UK approvals this year, with global commercialization targeting $1.5 billion in peak sales. In the US, pricing exceeds $10,000 per treatment, while India will offer it at 15-20% of that cost. Unlike generics, branded NCEs require physician education and direct marketing. Wockhardt will focus on hospital outreach for ICU-focused Zaynich, reducing costs compared to broader campaigns. Chairman Habil Khorakiwala emphasized building a commercial organization, outsourcing sales operations, and assembling medical, sales, and marketing leadership teams in the US and Europe. Wockhardt’s stock surged 16% intraday and closed 5.25% higher, outperforming benchmark Nifty Pharma by 46.86% over the past year. The company rejected partnerships with Big Pharma, opting to commercialize Zaynich independently. Analysts note the drug’s potential may limit the need for aggressive marketing, relying instead on targeted hospital engagement. This approval strengthens Wockhardt’s pipeline, with more NCEs expected in coming years. The shift from generics to branded drugs signals a strategic pivot, leveraging Zaynich’s success to establish a global presence in antibiotic innovation.